Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoKKPCF 69 Shareholder Yield % is 6.52% as of Mar. 2026, which is 74% above its 10-year median of 3.75. GuruFocus rates KKPCF with a GF Score™ of 69/100 and a GF Value™ of $25.42. The stock has 2 warning signs investors should review. Among 972 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks better than 86.01% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Kaken Pharmaceutical Co's Shareholder Yield % was 6.52%.
Kaken Pharmaceutical Co (OTCPK:KKPCF) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Kaken Pharmaceutical Co Shareholder Yield % Related Terms
Kaken Pharmaceutical Co Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Kaken Pharmaceutical Co's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KKPCF vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Kaken Pharmaceutical Co (KKPCF) has a Shareholder Yield % of 6.52% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kaken Pharmaceutical Co and its competitors. This is 74% above median its historical median of 3.75. Over the past decade, Kaken Pharmaceutical Co's Shareholder Yield % has ranged from 2.21 to 6.52. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #136 out of 972 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Kaken Pharmaceutical Co's Shareholder Yield % too high?
Kaken Pharmaceutical Co's current Shareholder Yield % of 6.52% is 74% above median its 10-year median of 3.75. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 6.52. The Drug Manufacturers industry median Shareholder Yield % is 0.29. Kaken Pharmaceutical Co's value of 6.52% is 2148.3% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #136 out of 972 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #136 out of 972 companies for Shareholder Yield %. This places Kaken Pharmaceutical Co in the top 14% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.29. Kaken Pharmaceutical Co's value of 6.52% is 2148.3% above this benchmark. Historically, Kaken Pharmaceutical Co's own Shareholder Yield % has ranged from 2.21 to 6.52 over the past decade. While the company's 10-year median is 3.75 vs. the industry median of 0.29, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.29, based on 972 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current Shareholder Yield % of 6.52% is 2148.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current Shareholder Yield % is 6.52%, which is 74% above median its own 10-year median of 3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current Shareholder Yield % of 6.52%. The stock's GF Value™ is $25.42, compared to a current price of $26.00 — trading 2.3% above its estimated fair value. The current Shareholder Yield % is 6.52%, which is 74% above median its 10-year median of 3.75 and 2148.3% above the Drug Manufacturers industry median of 0.29. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current Shareholder Yield % is 6.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of $26.00 is trading 2.3% above its estimated GF Value™ of $25.42.
Key valuation signals for KKPCF:
Shareholder Yield %: 6.52% (74% above median its 10-year median of 3.75)
GF Value™: $25.42 vs. price of $26.00 (2.3% above fair value)
Industry Position: 2148.3% above the Drug Manufacturers median (#136 of 972)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for KKPCF
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
